The amyloid beta precursor protein (APP) is one of the hallmark genes associated with Alzheimer’s disease (AD). As noted below, APP is a transmembrane protein that is sequentially cleaved by a class of proteases called secretases. Mutations adjacent to the gamma-secretase cleavage sites cause a dominantly inherited form of AD (DIAD), which is also often referred to autosomal dominant AD (ADAD), early onset AD (EOAD) or familial AD (FAD). APP emerged within the deep proteomic studies as a participant in Module 42 (M42), one of the core modules strongly associated with both cognitive decline and pathological progression in TREAT-AD investigations. As noted below, proteolytic processing of APP produces the amyloid peptide, definitional for AD type dementia. This project hopes to facilitate the investigation into APP’s role in AD pathology through the development or identification of high-quality antibodies, purified proteins, and bioinformatic resources as part of the TREAT-AD target enabling package (TEP) which will be shared with the scientific community.